Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy
Eli Lilly’s shiny new JAK2 inhibitor reduced spleen volume and symptom burden in an early-stage study of a rare chronic blood cancer called myelofibrosis, demonstrating a degree of efficacy that analysts said could position the drug as a “potentially best …